SCHEMBL4048668

SCHEMBL4048668

CSc1nc(-c2ccccc2)cs1.Cc1ccc(S(=O)(=O)O)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SREBF2 Q12772 1/20 0.41
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
PLAU P00749 1/20 0.39
C1S P09871 1/20 0.39
HTT P42858 1/20 0.38
PHGDH O43175 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050001 0.89 KDM1A (0.44) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL4050951 0.87 C1S (0.42) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL4050453 0.83 ALDH1A1 (0.41) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL4048678 0.81 PHGDH (0.46) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL4047725 0.77 HTR1A (0.58) MEN1KMT2ASREBF2RAB9ANPC1
SCHEMBL4050602 0.77 CASR (0.46) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL11705732 0.74 RAB9A (0.58) MEN1KMT2ASREBF2RAB9ANPC1
SCHEMBL4048676 0.74 PHGDH (0.48) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL4051276 0.73 FBP1 (0.41) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL26645 0.71 MEP1B (0.49) MEN1KMT2ATDP1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B MEN1 2905/4885KMT2A 531/4885SREBF2 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.